Search details
1.
The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.
Cell
; 184(15): 3949-3961.e11, 2021 07 22.
Article
in English
| MEDLINE | ID: mdl-34161776
2.
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
N Engl J Med
; 384(3): 238-251, 2021 01 21.
Article
in English
| MEDLINE | ID: mdl-33332778
3.
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
N Engl J Med
; 385(13): 1184-1195, 2021 09 23.
Article
in English
| MEDLINE | ID: mdl-34347950
4.
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.
N Engl J Med
; 385(23): e81, 2021 12 02.
Article
in English
| MEDLINE | ID: mdl-34587383
5.
Anti-SARS-CoV-2 IgA Identifies Asymptomatic Infection in First Responders.
J Infect Dis
; 225(4): 578-586, 2022 02 15.
Article
in English
| MEDLINE | ID: mdl-34636907
6.
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19.
J Infect Dis
; 227(1): 23-34, 2022 12 28.
Article
in English
| MEDLINE | ID: mdl-35895508
7.
Evaluation of EDB Fibronectin in Plasma, Patient-Derived Xenograft Formalin-Fixed Paraffin-Embedded and Fresh Frozen Tumor Tissues Using Immunoaffinity LC-MS/MS.
J Proteome Res
; 21(10): 2331-2340, 2022 Oct 07.
Article
in English
| MEDLINE | ID: mdl-36049057
8.
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
JAMA
; 327(5): 432-441, 2022 02 01.
Article
in English
| MEDLINE | ID: mdl-35029629
9.
Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors.
BMC Genomics
; 21(1): 2, 2020 Jan 02.
Article
in English
| MEDLINE | ID: mdl-31898484
10.
A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice.
Cancer Immunol Immunother
; 67(2): 247-259, 2018 02.
Article
in English
| MEDLINE | ID: mdl-29067496
11.
In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma.
Cancer Cell
; 11(3): 245-58, 2007 Mar.
Article
in English
| MEDLINE | ID: mdl-17349582
12.
Autoimmunity and tumor immunity induced by immune responses to mutations in self.
Nat Med
; 12(2): 198-206, 2006 Feb.
Article
in English
| MEDLINE | ID: mdl-16444264
13.
Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes.
Nat Med
; 12(5): 557-67, 2006 May.
Article
in English
| MEDLINE | ID: mdl-16648859
14.
Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles.
Sci Rep
; 13(1): 12784, 2023 08 07.
Article
in English
| MEDLINE | ID: mdl-37550377
15.
Nasopharyngeal Viral Load Is the Major Driver of Incident Antibody Immune Response to SARS-CoV-2 Infection.
Open Forum Infect Dis
; 10(12): ofad598, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-38111750
16.
Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double-Blind Trial.
Open Forum Infect Dis
; 10(5): ofad211, 2023 May.
Article
in English
| MEDLINE | ID: mdl-37229174
17.
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration.
Nat Commun
; 14(1): 3605, 2023 06 17.
Article
in English
| MEDLINE | ID: mdl-37330602
18.
Elevated serum IgA following vaccination against SARS-CoV-2 in a cohort of high-risk first responders.
Sci Rep
; 12(1): 14932, 2022 Sep 02.
Article
in English
| MEDLINE | ID: mdl-36056118
19.
A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors.
Front Immunol
; 13: 845417, 2022.
Article
in English
| MEDLINE | ID: mdl-35493516
20.
Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies.
mBio
; 13(6): e0169922, 2022 12 20.
Article
in English
| MEDLINE | ID: mdl-36255239